ILEI Inhibitors
ILEI inhibitors belong to a distinct chemical class that targets a specific molecular pathway within cellular processes. The term "ILEI" stands for Interleukin-like EMT inducer, a protein implicated in the regulation of epithelial-to-mesenchymal transition (EMT). EMT is a critical biological phenomenon that occurs during embryonic development and wound healing but is also aberrantly activated in various pathological conditions, including cancer metastasis. The inhibitors designed for ILEI function by modulating the activity of this key protein, thereby influencing the intricate balance between epithelial and mesenchymal states in cells.
ILEI inhibitors are characterized by their ability to selectively interact with the active sites or binding domains of the ILEI protein. This interaction impedes the normal signaling cascades associated with EMT, disrupting the molecular processes that contribute to cellular plasticity. By hampering EMT, these inhibitors hold promise in influencing cellular behavior and altering the course of diseases where EMT is dysregulated. The chemical class of ILEI inhibitors represents a targeted approach in the realm of molecular pharmacology, with researchers exploring the intricate details of their interactions with the ILEI protein to gain insights into the broader implications for cellular dynamics.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib inhibits epidermal growth factor receptor (EGFR), a protein upstream of ILEI in the EMT pathway. By inhibiting EGFR, erlotinib can reduce ILEI activity. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is another EGFR inhibitor, working similarly to erlotinib to decrease ILEI activity indirectly. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib inhibits both EGFR and HER2/neu, upstream proteins in the EMT pathway, thus attenuating ILEI activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib inhibits multiple tyrosine protein kinases involved in cell proliferation and angiogenesis, indirectly affecting ILEI activity. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $197.00 $520.00 $1093.00 | 4 | |
By inhibiting multiple receptor tyrosine kinases, sunitinib can indirectly reduce ILEI activity. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib inhibits several tyrosine kinases, including BCR-ABL and c-KIT, thus can indirectly influence ILEI activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor, affecting several pathways that can indirectly impact ILEI activity. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
Nilotinib, like dasatinib, inhibits BCR-ABL and can indirectly affect ILEI activity. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Pazopanib targets multiple tyrosine kinases, indirectly influencing ILEI activity. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib inhibits VEGFR, EGFR, and RET kinases, indirectly affecting ILEI activity. | ||||||